Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Estey

Showing results (181-190 of 204) with videos related to

Pageof 21
Sort By:
Blood|October 1, 1996
Topotecan, a topoisomerase I inhibitor, is active in the treatment of myelodysplastic syndrome and chronic myelomonocytic leukemiaM Beran, H Kantarjian, S O'Brien, et al.
Leukemia|January 12, 2007
Levels of soluble HLA-I and beta2M in patients with acute myeloid leukemia and advanced myelodysplastic syndrome: association with clinical behavior and outcome of induction therapyM Albitar, M Johnson, K A Do, et al.
Blood|July 1, 1994
Levels of retinoblastoma protein expression in newly diagnosed acute myelogenous leukemiaS M Kornblau, H J Xu, W Zhang, et al.
Leukemia|December 15, 2007
A prognostic score for patients with lower risk myelodysplastic syndromeG Garcia-Manero, J Shan, S Faderl, et al.
Leukemia & Lymphoma|November 9, 2001
Leukapheresis reduces early mortality in patients with acute myeloid leukemia with high white cell counts but does not improve long- term survivalF J Giles, Y Shen, H M Kantarjian, et al.
Journal of Pain Research|April 29, 2026
Considerations for a Mind-Body Program for Latine Adults with Chronic Pain and Cognitive Impairment: A Qualitative Study with Healthcare ProvidersNatalia Giraldo-Santiago, Marlene E Cardoza, Esther E E Estey, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 26, 1998
Low and maximally phosphorylated levels of the retinoblastoma protein confer poor prognosis in newly diagnosed acute myelogenous leukemia: a prospective studyS M Kornblau, M Andreeff, S X Hu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 1997
Phase I study of mitoxantrone plus etoposide with multidrug blockade by SDZ PSC-833 in relapsed or refractory acute myelogenous leukemiaS M Kornblau, E Estey, T Madden, et al.
Leukemia|August 19, 2017
Is there a need for morphologic exam to detect relapse in AML if multi-parameter flow cytometry is employed?Y Zhou, B L Wood, R B Walter, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 24, 1999
Topotecan and cytarabine is an active combination regimen in myelodysplastic syndromes and chronic myelomonocytic leukemiaM Beran, E Estey, S O'Brien, et al.
Pageof 21

Showing results (181-190 of 204) with videos related to

Sort By:
Pageof 21
Blood|October 1, 1996
Topotecan, a topoisomerase I inhibitor, is active in the treatment of myelodysplastic syndrome and chronic myelomonocytic leukemiaM Beran, H Kantarjian, S O'Brien, et al.
Leukemia|January 12, 2007
Levels of soluble HLA-I and beta2M in patients with acute myeloid leukemia and advanced myelodysplastic syndrome: association with clinical behavior and outcome of induction therapyM Albitar, M Johnson, K A Do, et al.
Blood|July 1, 1994
Levels of retinoblastoma protein expression in newly diagnosed acute myelogenous leukemiaS M Kornblau, H J Xu, W Zhang, et al.
Leukemia|December 15, 2007
A prognostic score for patients with lower risk myelodysplastic syndromeG Garcia-Manero, J Shan, S Faderl, et al.
Leukemia & Lymphoma|November 9, 2001
Leukapheresis reduces early mortality in patients with acute myeloid leukemia with high white cell counts but does not improve long- term survivalF J Giles, Y Shen, H M Kantarjian, et al.
Journal of Pain Research|April 29, 2026
Considerations for a Mind-Body Program for Latine Adults with Chronic Pain and Cognitive Impairment: A Qualitative Study with Healthcare ProvidersNatalia Giraldo-Santiago, Marlene E Cardoza, Esther E E Estey, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 26, 1998
Low and maximally phosphorylated levels of the retinoblastoma protein confer poor prognosis in newly diagnosed acute myelogenous leukemia: a prospective studyS M Kornblau, M Andreeff, S X Hu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 1997
Phase I study of mitoxantrone plus etoposide with multidrug blockade by SDZ PSC-833 in relapsed or refractory acute myelogenous leukemiaS M Kornblau, E Estey, T Madden, et al.
Leukemia|August 19, 2017
Is there a need for morphologic exam to detect relapse in AML if multi-parameter flow cytometry is employed?Y Zhou, B L Wood, R B Walter, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 24, 1999
Topotecan and cytarabine is an active combination regimen in myelodysplastic syndromes and chronic myelomonocytic leukemiaM Beran, E Estey, S O'Brien, et al.
Pageof 21